EBR Systems (ASX:EBR) said its manufacturing pre-approval inspection with the US Food and Drug Administration has been set for the week starting Jan. 6, 2025, according to a Thursday filing with the Australian bourse.
The inspection aims to confirm that the company's manufacturing, processing, and packing procedures adhere to quality system regulations, ensuring consistent device production meeting approved specifications, the filing said.
The US FDA initiated a review for the company's pre-market approval submission in late September, with the upcoming day-100 meeting scheduled for Friday, according to the filing.
Shares rose nearly 3% in midday trade Thursday.
Price (AUD): $0.89, Change: $+0.03, Percent Change: +2.91%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.